InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,230.00
(
-0.15%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,246.18
(
0.25%
)
Post# of 255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

georgejjl

Send PM Follow Ignore
Followers 138
Posts 23139
Boards Moderated 0
Alias Born 04/08/2004

georgejjl

Re: None

Wednesday, 09/22/2021 5:11:35 PM

Wednesday, September 22, 2021 5:11:35 PM

Post# of 255
AXO-Lenti-PD

•SIO plans to move to the third higher dose cohort in the study after which it expects to initiate the randomised, sham-controlled part of the SUNRISE-PD Phase 2 study in 2022

• Sales of products to treat Parkinson’s disease in the 7 major markets reached $3.1bn in 2016 and is forecast to reach $8.4bn by 2026

AXO-Lenti-PD achieves up to 10-fold increases in dopamine + L-dopa production compared to ProSavin (OXB-101), without impacting infusion volume or rate of administration

https://www.oxb.com/system/files/corporate-presentations/OXB%20Presentation%204%20May%2021%20w%20appendix.pdf

Good luck and GOD bless,
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up